Evaluating the potential of curcumin as a therapeutic agent for glioblastoma multiforme 2924

Abstract Description Glioblastoma Multiforme (GBM) is among the most aggressive and treatment-resistant brain cancers, characterized by rapid growth, high invasiveness, and poor prognosis. Current therapies offer limited efficacy, emphasizing the need for novel treatment approaches. This study investigates the efficacy of curcumin, a natural phytochemical, in reducing the viability of GBM cells using the U-87 MG human glioblastoma cell line. Cells were cultured and treated with curcumin dissolved in DMSO at varying concentrations, and viability was assessed using a trypan blue exclusion assay. Results demonstrated a dose-dependent reduction in cell proliferation, with the control group exhibiting approximately four times the cell count of the highest treatment concentration. These findings suggest that curcumin may offer a potential therapeutic strategy for glioblastoma, with reduced toxicity compared to conventional treatments. Further studies are needed to validate these results and explore the mechanisms underlying curcumin’s anti-cancer effects, including its role in apoptosis and cell cycle regulation. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)